Method of determining outcome of non small-cell lung cancer according to XRCC3 polymorphism

摘要

Method for determining a platinum-based chemotherapeutic regimen for treating Non-Small-Cell Lung cancer (NSCLC) in a patient comprising:
a) determining the presence or absence of the XRCC3 MetMet polymorphism in a biological sample from the patient,
c) determining a platinum-based chemotherapeutic regimen based on the presence or absence of the XRCC3 MetMet polymorphism in the sample,
wherein the presence of said polymorphism is indicative of favourable predisposition of said subject to respond to a chemotherapy treatment comprising the combination gemcitabine/cisplatin.